While other studies have tested inhibitors of PI3K and/or mTOR in EGFR-mutant NSCLC, our data provide a novel rationale for specifically testing Akt inhibitors in combination with EGFR TKIs in EGFR-mutant NSCLC patients that show Akt activation. The gene discussed is PIK3CA; the disease is non-small cell lung carcinoma.